Delpor

Executive Summary

Delpor is a clinical-stage biopharmaceutical company developing once-yearly injectable therapies for chronic CNS conditions, including schizophrenia, opioid use disorder, spasticity, Parkinson's, Alzheimer's, and multiple sclerosis. Founded in 2013 and based in San Francisco, the company leverages an innovative drug delivery platform designed to improve patient adherence and reduce dosing burden. Currently in Phase 1 development, Delpor's lead programs target high-need areas with limited long-acting options. The platform's potential to transform chronic disease management is promising, but the early stage and lack of disclosed pipeline details pose risks. Success will depend on demonstrating safety, tolerability, and sustained efficacy in upcoming clinical trials.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 clinical data readout for lead candidate (schizophrenia or opioid use disorder)30% success
• Q3 2026IND filing for second pipeline asset (e.g., Parkinson's or Alzheimer's)40% success
• TBDPotential platform licensing or partnership deal20% success